An Update on the Work of Oisin Biotechnologies: Building Therapies for Aging, Cancer, and Other Conditions by Targeting Harmful Cells for Destruction

Oisin Biotechnologies is a creation of our core community of longevity advocates, researchers, philanthropists, and others. The present CEO, Gary Hudson, was one of the first donors to support the newly formed Methuselah Foundation fifteen years ago. The company's seed funding was provided by the Methuselah Foundation and SENS Research Foundation a few years ago. A number of people in the audience here, myself included, invested in the company early last year in order to support this initiative. The initial goal of development at Oisin Biotechnologies is the targeted destruction of senescent cells, a path to produce one of the first working rejuvenation therapies to follow the SENS model of treating aging through damage repair. Matters are proceeding apace, as described in the interview below, and Oisin is presently raising a series A round of venture funding to continue the path to the clinic. The SENS approach is to identify and fix the root causes of aging, which are also the root causes of all age-related disease. Cellular senescence is one of these causes: a lingering population of senescent cells accumulate with age, a tiny leftover fraction of the constant flow of cells that become senescent and then, usually, self-destruct. The presence of a growing number of such leftover cells is a side-effect of the normal operation of metabolism, and is in effect a form of damage. Senescent cells generate signal molecules that spur chronic inflammation, create fibrosis, an...
Source: Fight Aging! - Category: Research Authors: Tags: Healthy Life Extension Community Source Type: blogs